MedTrace Logo

A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence

NCT06247241 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-12-05

No results posted yet for this study

Summary

The study drug VMB-100 is an mRNA encoding for IGF-1. It is administered by injection into the urethra sphincter, and taken up by the muscle cells. The IGF-1 acts to promote muscle regeneration in the sphincter, which is expected to improve the function of the sphincter and thereby alleviate incontinence (urinary leakage).

Conditions

  • Stress Urinary Incontinence

Interventions

DRUG

VMB-100

VMB-100 is administered as intrasphincteric injection in the urethra sphincter

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • Versameb AG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-11-30
Completion
2029-04-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06247241 on ClinicalTrials.gov